Rangers haven't ruled out Neftali Feliz starting

0 Comments

Neftali Feliz has pitched exclusively out of the bullpen since debuting last August and replaced Frank Francisco as the Rangers’ closer earlier this week, but general manager Jon Daniels wrote today in an online chat that the 22-year-old phenom may still end up in the rotation long term:

Going to depend on the makeup of the roster and how Neftali’s developing. Plenty of guys have relieved (or even closed) and then moved back to the rotation (Lowe, Dempster, Smoltz, Wainright, etc.). He’s not even 22 yet and has less than three months in the big leagues. We want him to get some experience under his belt–we have not abandoned the idea of him starting in the future, but that’s not our immediate focus.

Feliz was an elite prospect as a starter in the minors and I’m always of the opinion that young pitchers should be given an extended opportunity to show whether they can thrive for 200 innings per season before being moved to a role that limits them to 70 innings per season.
Getting his feet wet as a reliever isn’t a bad idea, especially given Francisco’s struggles and the bullpen’s overall lack of depth, but hopefully Daniels and the Rangers still have plans for Feliz as a starter.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
0 Comments

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.